Rapid Influenza Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afri

The global rapid influenza diagnostic tests market is witnessing accelerated growth as the demand for efficient, accessible, and accurate flu testing continues to rise. The market is projected to grow from US$ 970 million in 2025 to US$ 1.8 billion by 2032, registering a CAGR of 9.23% over the forecast period. Increased focus on early detection, widespread respiratory illness outbreaks, and rising adoption of point-of-care and home-based diagnostic solutions are contributing to the robust market expansion.

Market Insights

Rapid influenza diagnostic tests (RIDTs) have become essential tools in identifying influenza infections swiftly and effectively. The trend is shifting toward multiplex testing technologies that detect multiple pathogens in a single sample. For example, Roche’s cobas® Respiratory flex test, launched in , uses advanced TAGS technology to detect up to 12 respiratory viruses, including influenza A and B, RSV, and SARS-CoV-2, from a single patient sample.

Furthermore, home-based testing is gaining traction. In 2023, Lucira Health received FDA approval for its over-the-counter (OTC) COVID-19 & Flu Home Test, enabling users to self-test for flu A, flu B, and COVID-19, signaling a growing consumer preference for convenient diagnostics.

Key Growth Drivers

One of the primary drivers of market growth is continuous technological innovation in molecular and immunoassay-based diagnostics. Platforms such as Abbott’s ID NOW™ and BD’s Veritor™ Plus are improving test sensitivity and speeding up diagnostic time, making rapid tests more accurate and accessible in clinical settings.

Digital diagnostic tools are reducing manual errors and improving result interpretation, which is especially beneficial in busy healthcare environments. Enhanced accuracy and reliability are key factors fueling adoption in hospitals, clinics, and diagnostic labs.

Business Opportunity

The rising popularity of at-home testing presents a significant opportunity for market players. Regulatory bodies such as the FDA are actively supporting the development and commercialization of self-testing kits. These products reduce the strain on healthcare systems, facilitate early diagnosis, and prevent further transmission.

The launch of the Lucira COVID-19 & Flu Home Test marked a turning point in consumer diagnostics, indicating the high potential for growth in the OTC testing segment. Manufacturers focusing on user-friendly and affordable at-home test kits stand to benefit from expanding demand in both developed and emerging markets.

Regional Analysis

North America is expected to dominate the global market in 2025 with a 38.4% share. The region benefits from a robust healthcare infrastructure, high awareness levels, and quick regulatory approvals for new diagnostic solutions. The FDA’s recent clearance of multiple OTC flu tests highlights the region’s support for rapid diagnostic innovation.

East Asia is also emerging as a key market, projected to capture 20.3% of the global share by 2025. Government-led initiatives to strengthen disease surveillance, along with a skilled workforce and high production capacity, are driving demand. Notably, Kaneka Corporation’s dual antigen test launched in Japan in 2023 reflects growing investment in next-gen diagnostics across the region.

Competitive Analysis

The market is competitive and innovation-driven. Leading players such as Roche, Abbott, BD, and QuidelOrtho are continuously expanding their product portfolios with digital, multiplex, and molecular diagnostics.

Strategic developments include:
• Roche’s EUA approval for its cobas® liat SARS-CoV-2, Influenza A/B & RSV test in June
• SEKISUI Diagnostics’ EUA clearance for its OSOM Flu SARS-CoV-2 Combo Test in March
• Kaneka Corporation’s launch of a dual antigen test in Japan in 2023

These developments underscore the industry’s focus on combining flu diagnostics with COVID-19 detection, enhancing usability and broadening application in clinical and non-clinical settings.

Companies Covered

Major companies operating in the market include:
• QuidelOrtho Corporation
• BD
• Thermo Fisher Scientific Inc.
• Abbott
• F. Hoffmann-La Roche Ltd
• DiaSorin S.p.A.
• SEKISUI Diagnostics
• Kaneka Corporation
• Virax Biolabs
• ACCESS BIO
• Princeton BioMeditech Corporation
• LifeSign LLC.
• Pfizer Inc.
• McKesson Medical-Surgical Inc.
• iHealth Labs Inc.
• Flowflex UK

Market Segmentation

By Product Type
• Conventional
• Digital

By Test Type
• Influenza A Test
• Influenza B Test
• Influenza A+B Test

By Assay Type
• Immunochromatographic Assays
• Immunofluorescence Assays
• Nucleic Acid Amplification Test (NAAT)

By Sample Type
• Throat Swab
• Nasal Swab
• Nasal Aspirate
• Nasopharyngeal Swab
• Nasopharyngeal Aspirate
• Nasopharyngeal Wash

By End User
• Hospitals & Clinics
• Diagnostic Centers & Laboratories
• Nursing Homes
• Home Care Settings
• Others

By Region
• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Please note: Delivery Timelines - 5 working days. Show more